This proposal focuses on the protein called CFTR, mutations in which cause Cystic Fibrosis (CF), a major disease frequently characterized by chronic lung infections. CFTR is an ATP hydrolysis-dependent Cl- channel consisting of 2 membrane domains, 2 nucleotide binding folds (NBF1 plus NBF2), and an R (regulatory) domain. Most cases of CF are caused by a single mutation (deltaF508) in NBF1 which prevents CFTR from trafficking from the E.R. to the plasma membrane where, in the lung, it aids in combating infections. Early work (Science, 1991; JBC, 1992, 93, 94), supported by this grant, demonstrated that NBF1 and NBF2 bind ATP and that the deltaF508 mutation results in a folding problem. Recent work has shown that NBF1 hydrolyzes ATP (JBC, 1995), interacts with the membrane (Biochem., 1997), participates in the formation of an NBF1 plus R/NBF2 complex (In Review), and maintains the critical F508 region as an alpha-helix (In Review). Despite these important advances, essential information is lacking about the catalytic mechanism of NBF1 and NBF2, their """"""""cross-talk"""""""" in the NBF1 plus R/NBF2 complex, and the location and role of the F508 region. For these reasons, the following 4 hypotheses will be tested: 1. ATP hydrolysis catalyzed by NBF1 or NBF2 of CFTR proceeds through a reaction pathway similar to that catalyzed by both the F1 moiety of ATP synthase/ATPase complexes and myosin. 2. The rate of ATP hydrolysis is enhanced when the 3 """"""""soluble"""""""" domains of CFTR form a NBF1 plus R/NBF2 complex in which both NBF1 NBF2 are catalytic but function in an alternating, cooperative manner. 3. The F508 region of NBF1, which contains a potential catalytic base (E504), is flexible, and contributes to the active """"""""ATPase"""""""" site in the NBF1 plus R/NBF2 complex but lies outside this site in NBF1 alone. 4. The deltaF508 mutation responsible for most cases of CF prevents NBF1 from undergoing an ATP-dependent conformational change while reducing the catalytic efficiency of this domain. The proposed studies are fundamental to understanding structure/function relationships within CFTR, to understanding the underlying basis of most cases of CF, and to developing new strategies to treat the disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK043962-11
Application #
6624868
Study Section
Physical Biochemistry Study Section (PB)
Program Officer
Mckeon, Catherine T
Project Start
1991-05-01
Project End
2005-11-30
Budget Start
2002-12-01
Budget End
2005-11-30
Support Year
11
Fiscal Year
2003
Total Cost
$233,292
Indirect Cost
Name
Johns Hopkins University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Annereau, Jean Philippe; Ko, Young Hee; Pedersen, Peter L (2003) Cystic fibrosis transmembrane conductance regulator: the NBF1+R (nucleotide-binding fold 1 and regulatory domain) segment acting alone catalyses a Co2+/Mn2+/Mg2+-ATPase activity markedly inhibited by both Cd2+ and the transition-state analogue orthovanada Biochem J 371:451-62
Pedersen, Peter L (2002) Transport ATPases in biological systems and relationship to human disease: a brief overview. J Bioenerg Biomembr 34:327-32
Ko, Y H; Pedersen, P L (2001) Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease. J Bioenerg Biomembr 33:513-21
Massiah, M A; Ko, Y H; Pedersen, P L et al. (1999) Cystic fibrosis transmembrane conductance regulator: solution structures of peptides based on the Phe508 region, the most common site of disease-causing DeltaF508 mutation. Biochemistry 38:7453-61
Thomas, P J; Ko, Y H; Shenbagamurthi, P et al. (1995) Nucleotide domains in transport ATPases: structure-function and relationship to disease. Soc Gen Physiol Ser 50:17-28
Ko, Y H; Thomas, P J; Pedersen, P L (1994) The cystic fibrosis transmembrane conductance regulator. Nucleotide binding to a synthetic peptide segment from the second predicted nucleotide binding fold. J Biol Chem 269:14584-8
Thomas, P J; Pedersen, P L (1993) Effects of the delta F508 mutation on the structure, function, and folding of the first nucleotide-binding domain of CFTR. J Bioenerg Biomembr 25:11-9
Ko, Y H; Thomas, P J; Delannoy, M R et al. (1993) The cystic fibrosis transmembrane conductance regulator. Overexpression, purification, and characterization of wild type and delta F508 mutant forms of the first nucleotide binding fold in fusion with the maltose-binding protein. J Biol Chem 268:24330-8
Thomas, P J; Ko, Y H; Pedersen, P L (1992) Altered protein folding may be the molecular basis of most cases of cystic fibrosis. FEBS Lett 312:7-9
Thomas, P J; Shenbagamurthi, P; Sondek, J et al. (1992) The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. J Biol Chem 267:5727-30